Polyphor a Swiss company recently presented promising data on Murepavadi belonging to novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA). This is the first new class of antibiotic against Gram-negative pathogens to reach advanced clinical development in over 40 years and it eliminated antibiotic-resistant bacteria in 11 of 12 pneumonia patients who took it, according to a small study the company conducted.
This finding was part of a presentation made in Vienna by Polyphor at the 27th European Congress of Clinical Microbiology and Infectious Diseases last week. and showed that Murepavadin (POL7080) treats Pseudomonas aeruginosa, a bacteria involved in hospital-acquired pneumonia, in which death rate from the infection is high to the tune of 20-50%..
It was emphasized in the presentation that
- Early initiation of effective antimicrobial treatment for PA pulmonary infections is critical and a strong predictor of mortality.
2 Multi-drug resistant (MDR) PA has become a global problem and, as such, treatment is becoming more challenging with limited options available. Murepavadin, by means of its novel and unique mechanism of action, is extremely active and is being developed as first line treatment for MDR cases. Data presented today at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) have shown a high rate of clinical cure (91%) and low rate of mortality (9%) at day 28 in a small patient group (12 patients), when treated with Murepavadin.
3 It was also demonstrated that multiple doses of Murepavadin were considered to be safe and with acceptable tolerability..
Dr Ignacio Martin-Loeches, St James’ Hospital, Trinity College, Dublin (Ireland) explained, “PA represents a significant threat to the most vulnerable hospital patients, including intensive care patients, those with depleted immune systems such as those with cancer, people with severe burns and premature babies in neonatal units. Treatment options are limited and so this new class of antibiotics is desperately needed.”
“New treatment options are urgently needed”, highlighted Prof. Antoni Torres, Respiratory Institute Hospital Clinic, Barcelona (Spain). “Today’s announcement that Murepavadin has shown positive benefits in the trials offers hope for the management of this challenging patient group.”
Dr Glenn Dale, Head of Early Development, Antimicrobials, Polyphor added, “Murepavadin’s single pathogen focus prevents a build-up of resistance against other pathogens, which is a common problem with antibiotics. Today’s findings show that our proposed dose of Murepavidin could be a promising new antimicrobial to treat PA. This year, we expect Murepavadin to enter Phase III trials and take another step to bring it to patients. In addition, our OMPTA platform could bring further new important therapies in the treatment of Gram-negative pathogens.”